NO20062082L - Pellets inneholdende venlafaksinhydroklorid - Google Patents

Pellets inneholdende venlafaksinhydroklorid

Info

Publication number: NO20062082L
Authority: NO; Norway
Prior art keywords: venlafaxine hydrochloride; pellets; pellets containing; weight; containing venlafaxine
Prior art date: 2003-10-10

Application number

NO20062082A

Other languages

English (en)

Norwegian (no)

Inventor

Pal Fekete

Tibor Korbely

Agnes Bozso

Eszter Moricz

Original Assignee

Egyt Gyogyszervegyeszeti Gyar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-10

Filing date

2006-05-09

Publication date

2006-05-09

2006-05-09 Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar

2006-05-09 Publication of NO20062082L publication Critical patent/NO20062082L/no

Links

239000008188 pellet Substances 0.000 title abstract 4
229960002416 venlafaxine hydrochloride Drugs 0.000 title abstract 3
QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 title abstract 3
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 abstract 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
239000000654 additive Substances 0.000 abstract 1
238000013270 controlled release Methods 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
239000008108 microcrystalline cellulose Substances 0.000 abstract 1
229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
239000001103 potassium chloride Substances 0.000 abstract 1
235000011164 potassium chloride Nutrition 0.000 abstract 1
239000011780 sodium chloride Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Inorganic Chemistry (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO20062082A 2003-10-10 2006-05-09 Pellets inneholdende venlafaksinhydroklorid NO20062082L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU0303382A HUP0303382A2 (hu)	2003-10-10	2003-10-10	Venlafaxin-hidroklorid-tartalmú pelletek
PCT/HU2004/000095 WO2005034930A1 (en)	2003-10-10	2004-10-08	Pellets containing venlafaxine hydrochloride

Publications (1)

Publication Number	Publication Date
NO20062082L true NO20062082L (no)	2006-05-09

Family

ID=90001704

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20062082A NO20062082L (no)	2003-10-10	2006-05-09	Pellets inneholdende venlafaksinhydroklorid

Country Status (22)

Country	Link
EP (1)	EP1677777B1 (de)
CN (1)	CN1882321B (de)
AT (1)	ATE359771T1 (de)
AU (1)	AU2004280132B2 (de)
BG (1)	BG109539A (de)
CY (1)	CY1106693T1 (de)
CZ (1)	CZ2006269A3 (de)
DE (1)	DE602004006009T2 (de)
DK (1)	DK1677777T3 (de)
EA (1)	EA009695B1 (de)
ES (1)	ES2285538T3 (de)
HR (2)	HRP20060136A2 (de)
HU (1)	HUP0303382A2 (de)
IL (1)	IL174830A (de)
NO (1)	NO20062082L (de)
PL (2)	PL379541A1 (de)
PT (1)	PT1677777E (de)
RS (2)	RS52150B (de)
SI (1)	SI1677777T1 (de)
SK (1)	SK50442006A3 (de)
UA (1)	UA82268C2 (de)
WO (1)	WO2005034930A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE526950T1 (de)	1999-10-29	2011-10-15	Euro Celtique Sa	Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
EP2283829A1 (de)	2000-10-30	2011-02-16	Euro-Celtique S.A.	Hydrocodon-Formulierungen mit gesteuerter Freisetzung
IL146462A (en)	2001-11-13	2015-02-26	Lycored Bio Ltd	Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
WO2007016315A2 (en) *	2005-07-28	2007-02-08	Dr. Reddy's Laboratories Ltd.	Extended release venlafaxine compositions
WO2007135470A1 (en) *	2006-05-19	2007-11-29	EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság	Process for the preparation and surface coating of pellets
US8445018B2 (en)	2006-09-15	2013-05-21	Cima Labs Inc.	Abuse resistant drug formulation
WO2011143119A1 (en) *	2010-05-11	2011-11-17	Cima Labs Inc.	Alcohol-resistant extended release dosage forms comprising venlafaxine
CA2798702A1 (en)	2010-05-11	2011-11-17	Cima Labs Inc.	Alcoholresistant metoprolol-containing extended-release oral dosage forms
US20160367502A1 (en) *	2012-12-19	2016-12-22	Ratiopharm Gmbh	Film coated pellets
CN103893151B (zh) *	2012-12-31	2018-04-27	石药集团中奇制药技术（石家庄）有限公司	一种盐酸文拉法辛缓释胶囊及其制备方法
US20150118300A1 (en)	2013-10-31	2015-04-30	Cima Labs Inc.	Immediate Release Abuse-Deterrent Granulated Dosage Forms
US12589083B2 (en)	2019-05-07	2026-03-31	Clexio Biosciences Ltd.	Abuse-deterrent dosage forms containing esketamine
EP3965733A4 (de)	2019-05-07	2023-01-11	Clexio Biosciences Ltd.	Esketamin enthaltende missbrauchssichere darreichungsformen
CN114028577B (zh) *	2021-10-20	2024-07-02	珠海市东辰制药有限公司	一种二氧化硅丸芯及其制备方法
CN119868294B (zh) *	2024-11-08	2026-02-03	迪沙药业集团有限公司	一种利格列汀药物组合物及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1331003B1 (de) *	1996-03-25	2015-08-26	Wyeth LLC	Venlafaxinhaltige Arzneizusammensetzung mit verzögerter Wirkstoffabgabe
PE57198A1 (es) *	1996-03-25	1998-10-10	American Home Prod	Formula de liberacion prolongada
UA77145C2 (en) *	1997-11-05	2006-11-15	Wyeth Corp	Extended release dosage formulation
CN1334080A (zh) *	2001-07-25	2002-02-06	成都康弘制药有限公司	盐酸万拉法新缓释片及其制备方法
IL146462A (en) *	2001-11-13	2015-02-26	Lycored Bio Ltd	Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
AU2003219117A1 (en) *	2002-03-28	2003-10-13	Synthon B.V.	Extended release venlafaxine formulations

2003
- 2003-10-10 HU HU0303382A patent/HUP0303382A2/hu unknown
2004
- 2004-08-10 UA UAA200605099A patent/UA82268C2/uk unknown
- 2004-10-08 RS RS20060252A patent/RS52150B/sr unknown
- 2004-10-08 EP EP04791654A patent/EP1677777B1/de not_active Expired - Lifetime
- 2004-10-08 EA EA200600675A patent/EA009695B1/ru not_active IP Right Cessation
- 2004-10-08 PL PL379541A patent/PL379541A1/pl not_active IP Right Cessation
- 2004-10-08 RS YUP-2006/0252A patent/RS20060252A/sr unknown
- 2004-10-08 PT PT04791654T patent/PT1677777E/pt unknown
- 2004-10-08 CN CN2004800330326A patent/CN1882321B/zh not_active Expired - Fee Related
- 2004-10-08 HR HR20060136A patent/HRP20060136A2/xx not_active Application Discontinuation
- 2004-10-08 DK DK04791654T patent/DK1677777T3/da active
- 2004-10-08 WO PCT/HU2004/000095 patent/WO2005034930A1/en not_active Ceased
- 2004-10-08 DE DE602004006009T patent/DE602004006009T2/de not_active Expired - Lifetime
- 2004-10-08 ES ES04791654T patent/ES2285538T3/es not_active Expired - Lifetime
- 2004-10-08 PL PL04791654T patent/PL1677777T3/pl unknown
- 2004-10-08 AU AU2004280132A patent/AU2004280132B2/en not_active Ceased
- 2004-10-08 HR HR20070322T patent/HRP20070322T3/xx unknown
- 2004-10-08 AT AT04791654T patent/ATE359771T1/de active
- 2004-10-08 SK SK5044-2006A patent/SK50442006A3/sk unknown
- 2004-10-08 SI SI200430364T patent/SI1677777T1/sl unknown
- 2004-10-08 CZ CZ20060269A patent/CZ2006269A3/cs unknown
2006
- 2006-04-06 IL IL174830A patent/IL174830A/en not_active IP Right Cessation
- 2006-05-09 NO NO20062082A patent/NO20062082L/no unknown
- 2006-05-10 BG BG109539A patent/BG109539A/bg unknown
2007
- 2007-07-02 CY CY20071100874T patent/CY1106693T1/el unknown

Also Published As

Publication number	Publication date
AU2004280132B2 (en)	2009-10-22
PT1677777E (pt)	2007-06-21
CZ2006269A3 (cs)	2006-07-12
UA82268C2 (uk)	2008-03-25
EA200600675A1 (ru)	2006-08-25
CN1882321B (zh)	2011-06-08
HUP0303382A2 (hu)	2005-08-29
IL174830A (en)	2010-04-15
EP1677777B1 (de)	2007-04-18
HK1098364A1 (en)	2007-07-20
DE602004006009T2 (de)	2008-01-10
DK1677777T3 (da)	2007-09-03
WO2005034930A1 (en)	2005-04-21
CN1882321A (zh)	2006-12-20
ATE359771T1 (de)	2007-05-15
BG109539A (bg)	2006-11-30
HRP20070322T3 (hr)	2007-09-30
AU2004280132A1 (en)	2005-04-21
RS52150B (sr)	2012-08-31
DE602004006009D1 (de)	2007-05-31
SI1677777T1 (sl)	2007-10-31
PL379541A1 (pl)	2006-10-02
PL1677777T3 (pl)	2007-08-31
CY1106693T1 (el)	2012-05-23
HRP20060136A2 (en)	2006-06-30
EA009695B1 (ru)	2008-02-28
IL174830A0 (en)	2008-04-13
EP1677777A1 (de)	2006-07-12
HUP0303382D0 (en)	2003-12-29
RS20060252A (sr)	2008-08-07
ES2285538T3 (es)	2007-11-16
SK50442006A3 (sk)	2006-08-03

Publication	Publication Date	Title
CY1106693T1 (el)	2012-05-23	Πελετες οι οποιες περιεχουν υδροχλωρικη βενλαφαξινη
NO20073959L (no)	2007-09-27	Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
NO20053681L (no)	2005-08-23	Dispersjon av smaksmaskerte krystaller eller granuler av aktive forbindelser, tyggbare blote kapsler fylt med nevnte dispersjon og fremgangsmate for fremstilling derav
JP2018513852A5 (de)	2019-05-16
RU2005115855A (ru)	2006-01-20	Композиция трамадола продлонгированного высвобождением с 24-часовым действием
NO20082047L (no)	2008-04-29	Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
HRP20171518T1 (hr)	2017-11-17	Tabletni pripravak bez prouzrokovanja kvarova kod tabletiranja
HRP20192026T4 (hr)	2023-03-31	Formulacija tableta od neratinib maleata
NO20083104L (no)	2008-09-19	Fast preparat
NO20045072L (no)	2005-01-20	Tablett med hoyt medikamentinnhold
MX2010007672A (es)	2010-10-07	Composicion estabilizada de liberacion sostenida de clorhidrato de bupropion y proceso para su preparacion.
ATE516796T1 (de)	2011-08-15	Granulat mit einem pharmazeutischen wirkstoff und einem emulgator und herstellungsverfahren dafür
JO2973B1 (en)	2016-03-15	Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
MX2010003923A (es)	2010-05-05	Formulacion farmaceutica de valsartan.
NO20082265L (no)	2008-05-16	Dispergerbare tabletter som innbefatter deferasirox
GEP20043285B (en)	2004-07-26	Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections
NO341573B1 (no)	2017-12-04	Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
ATE329581T1 (de)	2006-07-15	Pharmazeutische formulierung, die n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydr -2h-(1, 3)oxazino(3,2-a)indol-10-carboxamid oder ein entsprechendes salz hiervon enthält, sowie deren herstellungsprozess, welcher trockengranulierung beinhaltet
RU2014119866A (ru)	2015-11-27	Твердые дозированные формы (s)-этил 2-амино-3-(2-амино-6(r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата
WO2007123883A3 (en)	2008-03-27	Oral dosage formulations and methods of preparing the same
NZ560669A (en)	2012-09-28	Use of alkyl cellulose as controlled release matrix material in alcohol resistant dosage forms
NO20070952L (no)	2007-03-20	Formuleringer av suberoylanilidhydroksaminsyre og fremgangsmate for fremstilling av slike
JP2011516544A5 (de)	2013-08-01
MY139086A (en)	2009-08-28	Use of debranched starch in extrusion-spheronization pharmaceutical pellets
NO20073702L (no)	2007-09-28	Ikke-steroid glukocorticoid reseptor modulatorer